COVID-19: Lilly antibody treatment trial paused over safety concern
Pharma giant pauses late-stage trial of experimental lab-produced antibody treatment
Image Credit: Shutterstock
Washington: US pharmaceutical firm Eli Lilly on Tuesday paused a late-stage trial of its experimental lab-produced antibody treatment against COVID-19 over an unspecified safety concern, the company said.
“Lilly is supportive of the decision by the independent DSMB (data safety monitoring board) to cautiously ensure the safety of the patients participating in this study,” a spokesperson said in a statement.